# Phase 3 Triiodothyronine Supplementation for Infants After Cardiopulmonary Bypass

Study · id `cardio:ct-nct02320669` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02320669](<https://clinicaltrials.gov/study/NCT02320669>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02320669

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 220 participants.

## Technical summary

Registry record NCT02320669. Randomized; triple masking; primary purpose treatment. Start 2014-11 (registry gives no type); primary completion 2019-10 (actual). Results posted on 2024-04-09.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 220 participants (enrolled count; ClinicalTrials.gov record NCT02320669, source copy `cardio:ctgov-nct02320669-2024-04-09`, retrieved 2026-10-26)
- Start date: 2014-11 (registry gives no type) (ClinicalTrials.gov record NCT02320669, source copy `cardio:ctgov-nct02320669-2024-04-09`, retrieved 2026-10-26)
- Primary completion: 2019-10 (actual) (ClinicalTrials.gov record NCT02320669, source copy `cardio:ctgov-nct02320669-2024-04-09`, retrieved 2026-10-26)
- Completion: 2019-10 (actual) (ClinicalTrials.gov record NCT02320669, source copy `cardio:ctgov-nct02320669-2024-04-09`, retrieved 2026-10-26)
- Results first posted: 2024-04-09 (ClinicalTrials.gov record NCT02320669, source copy `cardio:ctgov-nct02320669-2024-04-09`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT02320669, source copy `cardio:ctgov-nct02320669-2024-04-09`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02320669-2024-04-09`, retrieved 2026-10-26)

## The registry's words

- Brief title: Phase 3 Triiodothyronine Supplementation for Infants After Cardiopulmonary Bypass
- Acronym: TRICC-2
- Condition: Congenital Heart Defects
- Intervention (Drug): Triostat
- Intervention (Drug): Placebo
- Lead sponsor: Seattle Children's Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Congenital heart disease (`core:congenital-heart-disease`)

### Other papers using this trial's data

- Registry lists this paper as a reference of type result; PubMed dates it on or after the trial start and types it as a trial report, neither its types nor its title mark it as a protocol, a review or a comment, the paper names no other trial in place of this one, and PubMed shows no retraction or expression of concern; it is not marked as the trial's main report: Triiodothyronine Supplementation in Infants Undergoing Cardiopulmonary Bypass: A Randomized Controlled Trial (`cardio:pubmed-35093535`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: a8d61e98479e90b4f9485f51fb6bbea4e371d4700a87b6d608daa65983bf321f
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
